FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362677780> ?p ?o ?g. }

• W4362677780 endingPage "1061" @default.
• W4362677780 startingPage "1056" @default.
• W4362677780 abstract "Neuroendocrine tumors (NETs) are often diagnosed in advanced stages. Despite the advances in treatment approaches, including somatostatin analogs and peptide receptor radionuclide therapy (PRRT), these patients have no curative treatment option. Moreover, immunotherapy often yields modest results in NETs. We investigated whether combining PRRT using [¹⁷⁷Lu]DOTATATE and immune checkpoint inhibition therapy improves treatment response in NETs. <b>Methods:</b> A gastroenteropancreatic NET model was generated by subcutaneous implantation of human QGP-1 cells in immune-reconstituted NOD.Cg-<i>Prkdc^scid Il2rg^tm1Wjl</i>/SzJ mice engrafted with human peripheral blood mononuclear cells (<i>n</i> = 96). Mice were randomly assigned to receive pembrolizumab (anti-PD1), [¹⁷⁷Lu]DOTATATE (PRRT), simultaneous anti-PD1 and PRRT (S-PRRT), anti-PD1 on day 0 followed by PRRT on day 3 (delayed PRRT [D-PRRT]), PRRT on day 0 followed by anti-PD1 (early PRRT [E-PRRT]), or vehicle as control (<i>n</i> = 12/group). Human granzyme-B–specific [⁶⁸Ga]NOTA-hGZP PET/MRI was performed before and 6 d after treatment initiation, as an indicator of T-cell activation. Response to treatment was based on tumor growth over 21 d and on histologic analyses of extracted tissues on flow cytometry for T cells, hematoxylin and eosin staining, and immunohistochemical staining. <b>Results:</b> [⁶⁸Ga]NOTA-hGZP PET/MRI showed significantly increased uptake in tumors treated with E-PRRT, S-PRRT, and anti-PD1 on day 6 compared with baseline (SUV_max: 3.36 ± 0.42 vs. 0.73 ± 0.23; 2.36 ± 0.45 vs. 0.76 ± 0.30; 2.20 ± 0.20 vs. 0.72 ± 0.28, respectively; <i>P</i> < 0.001), whereas no significant change was seen in PET parameters in the D-PRRT, PRRT, or vehicle groups (<i>P</i> > 0.05). Ex vivo analyses confirmed the PET results showing the highest granzyme-B levels and T cells (specifically CD8-positive effector T cells) in the E-PRRT group, followed by the S-PRRT and anti-PD1 groups. Tumor growth follow-up showed the most significant tumor size reduction in the E-PRRT group (baseline to day 21, 205.00 ± 30.70 mm³ vs. 78.00 ± 11.75 mm³; <i>P</i> = 0.0074). Tumors showed less growth reduction in the PRRT, D-PRRT, and S-PRRT groups than in the E-PRRT group (<i>P</i> < 0.0001). The vehicle- and anti-PD-1–treated tumors showed continued growth. <b>Conclusion:</b> Combination of PRRT and anti-PD1 shows the most robust inflammatory response to NETs and a better overall outcome than immune checkpoint inhibition or PRRT alone. The most effective regimen is PRRT preceding anti-PD1 administration by several days." @default.
• W4362677780 created "2023-04-07" @default.
• W4362677780 creator A5006495863 @default.
• W4362677780 creator A5007635741 @default.
• W4362677780 creator A5021193022 @default.
• W4362677780 creator A5059436347 @default.
• W4362677780 creator A5063494562 @default.
• W4362677780 date "2023-04-06" @default.
• W4362677780 modified "2023-10-18" @default.
• W4362677780 title "Addition of Peptide Receptor Radiotherapy to Immune Checkpoint Inhibition Therapy Improves Outcomes in Neuroendocrine Tumors" @default.
• W4362677780 cites W2031301095 @default.
• W4362677780 cites W2052727153 @default.
• W4362677780 cites W2053825882 @default.
• W4362677780 cites W2104347254 @default.
• W4362677780 cites W2110710958 @default.
• W4362677780 cites W2135049144 @default.
• W4362677780 cites W2139327979 @default.
• W4362677780 cites W2148617171 @default.
• W4362677780 cites W2150633526 @default.
• W4362677780 cites W2222086386 @default.
• W4362677780 cites W2573369749 @default.
• W4362677780 cites W2578888194 @default.
• W4362677780 cites W2611333272 @default.
• W4362677780 cites W2617066209 @default.
• W4362677780 cites W2625330427 @default.
• W4362677780 cites W2751602305 @default.
• W4362677780 cites W2846786516 @default.
• W4362677780 cites W2897307381 @default.
• W4362677780 cites W2980748519 @default.
• W4362677780 cites W3002637272 @default.
• W4362677780 cites W3009875356 @default.
• W4362677780 cites W3153955088 @default.
• W4362677780 cites W3157076486 @default.
• W4362677780 cites W3198176993 @default.
• W4362677780 cites W3214048256 @default.
• W4362677780 cites W4225880044 @default.
• W4362677780 cites W4290888601 @default.
• W4362677780 doi "https://doi.org/10.2967/jnumed.123.265391" @default.
• W4362677780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37024303" @default.
• W4362677780 hasPublicationYear "2023" @default.
• W4362677780 type Work @default.
• W4362677780 citedByCount "1" @default.
• W4362677780 crossrefType "journal-article" @default.
• W4362677780 hasAuthorship W4362677780A5006495863 @default.
• W4362677780 hasAuthorship W4362677780A5007635741 @default.
• W4362677780 hasAuthorship W4362677780A5021193022 @default.
• W4362677780 hasAuthorship W4362677780A5059436347 @default.
• W4362677780 hasAuthorship W4362677780A5063494562 @default.
• W4362677780 hasConcept C121608353 @default.
• W4362677780 hasConcept C126322002 @default.
• W4362677780 hasConcept C204232928 @default.
• W4362677780 hasConcept C2776297358 @default.
• W4362677780 hasConcept C2777701055 @default.
• W4362677780 hasConcept C2779066768 @default.
• W4362677780 hasConcept C2780057760 @default.
• W4362677780 hasConcept C2781025020 @default.
• W4362677780 hasConcept C2989005 @default.
• W4362677780 hasConcept C2993559085 @default.
• W4362677780 hasConcept C71924100 @default.
• W4362677780 hasConceptScore W4362677780C121608353 @default.
• W4362677780 hasConceptScore W4362677780C126322002 @default.
• W4362677780 hasConceptScore W4362677780C204232928 @default.
• W4362677780 hasConceptScore W4362677780C2776297358 @default.
• W4362677780 hasConceptScore W4362677780C2777701055 @default.
• W4362677780 hasConceptScore W4362677780C2779066768 @default.
• W4362677780 hasConceptScore W4362677780C2780057760 @default.
• W4362677780 hasConceptScore W4362677780C2781025020 @default.
• W4362677780 hasConceptScore W4362677780C2989005 @default.
• W4362677780 hasConceptScore W4362677780C2993559085 @default.
• W4362677780 hasConceptScore W4362677780C71924100 @default.
• W4362677780 hasIssue "7" @default.
• W4362677780 hasLocation W43626777801 @default.
• W4362677780 hasLocation W43626777802 @default.
• W4362677780 hasOpenAccess W4362677780 @default.
• W4362677780 hasPrimaryLocation W43626777801 @default.
• W4362677780 hasRelatedWork W136083521 @default.
• W4362677780 hasRelatedWork W1518474861 @default.
• W4362677780 hasRelatedWork W1541368151 @default.
• W4362677780 hasRelatedWork W1862826322 @default.
• W4362677780 hasRelatedWork W1922636298 @default.
• W4362677780 hasRelatedWork W2092706522 @default.
• W4362677780 hasRelatedWork W2148617171 @default.
• W4362677780 hasRelatedWork W2744424417 @default.
• W4362677780 hasRelatedWork W2911101562 @default.
• W4362677780 hasRelatedWork W3031509828 @default.
• W4362677780 hasVolume "64" @default.
• W4362677780 isParatext "false" @default.
• W4362677780 isRetracted "false" @default.
• W4362677780 workType "article" @default.